Coming of age: Recombinant human thyroid-stimulating hormone as a preparation for 131I therapy in thyroid cancer

Journal of Nuclear Medicine

Volumn 44, Issue 7, 2003, Pages 1069-1071

  Robbins, Richard J ^a   Pentlow, Keith S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN;

DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE MARKER; FOOD AND DRUG ADMINISTRATION; HORMONAL REGULATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; NOTE; PRIORITY JOURNAL; RADIATION EXPOSURE; SIDE EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID CELL; THYROIDECTOMY; WHOLE BODY RADIATION; ADJUVANT CHEMOTHERAPY; AGE; BLOOD; COMPARATIVE STUDY; FEMALE; HALF LIFE TIME; MALE; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; RADIOMETRY; RETROSPECTIVE STUDY; THYROID TUMOR; WHOLE BODY COUNTING;

AGE FACTORS; CHEMOTHERAPY, ADJUVANT; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOMETRY; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; WHOLE-BODY COUNTING;

EID: 0041887021     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (24)

1. Haugen B, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
2. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:619-625.
3. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 2002;87:1490-1498.
4. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499-1501.
5. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-3247.
6. Taurog A. Hormone synthesis: thyroid iodine metabolism. In: Werner SC, ed. The Thyroid: A Fundamental and Clinical Text 4th ed. Hagerstown, MD: Harper & Row; 1978:31-61.
7. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 1995;24:803-839.
8. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002;27:767-771.
9. Montenegro J, Gonzalez O, Saracho R, Aguirre R, Martinez I. Changes in renal function in primary hypothyroidism Am J Kidney Dis. 1996;27:195-198.
10. Villabona C, Sahun M, Roca M, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci. 1999;318:277-280.
11. Park S-G, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism [abstract]. J Nucl Med 1996;37(suppl):15P
12. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994;78:188-196.
13. Lippi F, Capezzone M, Angelini F, et al Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol. 2001;144:5-11
14. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2000;85:3640-3645.
15. Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999;84:3228-3234.
16. Yoshida A, Hatton K, Hisatome I, et al. A TSH/ dibutyryl cAMP activated CI-/I- channel in FRTL-5 cells. Biochem Biophys Res Commun. 1999;259:631-635.
17. Yoshida A, Taniguchi S, Hisatome I, et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab. 2002;87:3356-3361.
18. 131I. J Nucl Med. 2003;44:1065-1068.
19. Luster M, Sherman S, Skarulis M, et al. The impact of I-131 diagnostic activities on biokinetics of thyroid remnants [abstract ]. Eur J Nucl Med. 2002;29(suppl 1):A465.
20. de Keizer B, Brans B, Hoekstra A, et al Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging. 2003;30:367-373
21. Maxon HR, Thomas SR, Hertzberg VS, et al Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer N Engl J Med. 1983;309:937-941.
22. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482-1488.
23. Robbins RJ, Larson SM, Pentlow KS, Tuttle RM Effectiveness of I-131 in destroying metastatic thyroid cancer lesions. In: Program of the 74th Annual Meeting of the American Thyroid Association; 2002; Los Angeles, CA: 199.
24. Nijhuis T, van Weperen W, de Klerk JH. Cost associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd. 1999;21:98-100.